Sensorion Announces an Increase in Resources Allocated to the Liquidity Contract with Kepler Cheuvreux

About this update from Sensorion Sas

[{"type":"text","content":"MONTPELLIER, France, August 15, 2025--(BUSINESS WIRE)--Regulatory News:","length":71,"tagName":"p"},{"type":"text","content":"Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss disorders, today announces an increase in resources allocated to the liquidity contract entrusted to Kepler Cheuvreux.","length":295,"tagName":"p"},{"type":"text","content":"On 15 December 2017 Sensorion entered into a Liquidity Contract with Kepler Cheuvreux, modified by amendments dated 7 December 2018 and 15 July 2022 (the "Contract"). This Contract aims to promote the liquidity of the Shares of Sensorion on Euronext Paris.","length":266,"tagName":"p"},{"type":"text","content":"On 14 August 2025, in accordance with Article 4 of AMF Decision No. 2021-01 of 22 June 2021 renewing the establishment of liquidity contracts on equity securities as an accepted market practice, Sensorion increased the resources allocated to the liquidity contract by €60,000.","length":276,"tagName":"p"},{"type":"text","content":"Following this increase in resources, as of 14 August 2025, the following assets appear on the liquidity account:","length":113,"tagName":"p"},{"type":"text","content":"- 206,211 Sensorion Ordinary Shares- €66,965.21","length":48,"tagName":"p","attribs":{}},{"type":"text","content":"About SensorionSensorion is a pioneering clinical-stage biotech company, which specializes in the development of novel therapies to restore, treat, and prevent hearing loss disorders, a significant global unmet medical need. Sensorion has built a unique R&D technology platform to expand its understanding of the pathophysiology and etiology of inner ear related diseases, enabling it to select the best targets and mechanisms of action for drug candidates.It has two gene therapy programs aimed at correcting hereditary monogenic forms of deafness, developed in the framework of its broad strategic collaboration focused on the genetics of hearing with the Institut Pasteur. SENS-501 (OTOF-GT) currently being developed in a Phase 1/2 clinical trial, targets deafness caused by mutations of the gene encoding for otoferlin and GJB2-GT targets hearing loss related to mutations in GJB2 gene to potentially address important hearing loss segments in ad...

More updates from Sensorion Sas